Rilvegostomig is a PD-1/TIGIT bispecific antibody in late-stage oncology development. Public trial records show active Phase III evaluation in combination with chemotherapy as adjuvant therapy for biliary tract cancer after curative-intent resection. It remains investigational and has no marketing approval.
Compugen said it will release fourth quarter and full year 2025 results on March 2, 2026, and present at the Needham Virtual Healthcare Conference on April 13. The company also outlined its Phase 1 and Phase 3 immuno-oncology pipeline programs.
AstraZeneca will report pivotal first-half data on sonesitatug vedotin in Claudin18.2 gastric cancer. The phase 3 Clarity-Gastric01 study is enrolling patients with ≥25% expression.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07431281 |
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 |
RECRUITING | PHASE3 |
| NCT07221253 |
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) |
RECRUITING | PHASE3 |
| NCT07115043 |
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07098338 |
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) |
RECRUITING | PHASE2 |
| NCT07069712 |
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma |
RECRUITING | PHASE2 |
| NCT06996782 |
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) |
RECRUITING | PHASE1/PHASE2 |
| NCT06989112 |
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer |
RECRUITING | PHASE3 |
| NCT06921785 |
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma |
RECRUITING | PHASE3 |
| NCT06868277 |
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer |
RECRUITING | PHASE3 |
| NCT06764875 |
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer |
RECRUITING | PHASE3 |
